Trial Profile
A randomised phase IV study to compare two rates of dosage tapering, when switching patients to aripiprazole from other atypical antipsychotics for the treatment of schizophrenia and schizoaffective disorder.
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 17 Jun 2016
Price :
$35
*
At a glance
- Drugs Aripiprazole (Primary) ; Olanzapine
- Indications Schizoaffective disorder; Schizophrenia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 03 Sep 2011 New trial record